X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-10-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $74.81 | -7,000 | 31,771 | -18% | -$523,648 | |||||
| D | 2026-10-14 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $49.26 | -1,040 | 95,857 | -1% | -$51,230 | |||||
| D | 2026-10-14 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $49.26 | -4,098 | 259,736 | -2% | -$201,867 | |||||
| D | 2026-10-13 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $350.99 | -31,027 | 9,566,326 | 0% | -$10,890,074 | |||||
| D | 2026-10-15 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.00 | -1,452 | 117,227 | -1% | -$36,300 | |||||
| M | 2026-10-13 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +9,569 | 955,493 | +1% | +$12,719 | |||||
| D | 2026-10-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $539.99 | -9,500 | 668,728 | -1% | -$5,129,873 | |||||
| D | 2026-10-13 | TRXB | Trex Bio, Inc. | Alexandria Venture Investments, LLC | 10% | P - Purchase | $14.00 | +178,571 | 1,346,501 | +15% | +$2,499,994 | |||||
| M | 2026-10-13 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.36 | +110,000 | 1,753,000 | +7% | +$920,049 | |||||
| D | 2026-10-14 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | Co-Chief Scientific Officer | S - Sale+OE | $772.70 | -4,147 | 52,247 | -7% | -$3,204,376 | |||||
2026-10-13 | BIOF | Blue Biofuels, Inc. | Kneppers Chris J | Dir | S - Sale | $0.10 | -100,000 | 19,872,677 | -1% | -$10,000 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Ray Sumita | Chief Legal Compliance Officer | S - Sale | $28.05 | -1,844 | 116,701 | -2% | -$51,724 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S - Sale | $28.05 | -1,144 | 47,817 | -2% | -$32,089 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Lin Shao-Lee | CEO | S - Sale | $27.55 | -11,087 | 694,908 | -2% | -$305,490 | ||||||
2026-10-14 | ZONE | Zone Frontier Inc. | Hassen Tyler Lewis | CEO | P - Purchase | $0.11 | +750,000 | 4,000,000 | +23% | +$85,200 | ||||||
| M | 2026-10-12 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | S - Sale | $130.16 | -27,500 | 146,132 | -16% | -$3,579,476 | |||||
2026-10-14 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $84.56 | +10,040 | 970,453 | +1% | +$848,977 | ||||||
2026-10-12 | ELF | E.L.F. Beauty, Inc. | Franks Joshua Allen | SVP, Operations | S - Sale | $110.01 | -8,366 | 126,931 | -6% | -$920,310 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $8.32 | -3,221 | 340,038 | -1% | -$26,798 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $8.32 | -1,301 | 137,170 | -1% | -$10,824 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $8.32 | -917 | 163,131 | -1% | -$7,629 | ||||||
2026-10-12 | CDXS | Codexis, Inc. | Erbez Georgia | See Remarks | S - Sale | $1.36 | -6,335 | 60,475 | -9% | -$8,619 | ||||||
2026-10-12 | CDXS | Codexis, Inc. | Moore Alison | Pres, CEO | S - Sale | $1.36 | -6,335 | 244,171 | -3% | -$8,619 | ||||||
| D | 2026-10-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $545.52 | -9,500 | 668,728 | -1% | -$5,182,414 | |||||
| D | 2026-10-14 | NRIX | Nurix Therapeutics, Inc. | Gregory Julia P | Dir | S - Sale+OE | $23.40 | -22,583 | 10,750 | -68% | -$528,528 | |||||
| AM | 2024-10-28 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $1.50 | -287,845 | 13,396,000 | -2% | -$432,044 | |||||
| D | 2026-10-12 | INKT | Mink Therapeutics, Inc. | Buell Jennifer | CEO | S - Sale+OE | $10.56 | -6,938 | 74,195 | -9% | -$73,265 | |||||
2026-10-09 | OCGN | Ocugen, Inc. | Musunuri Shankar | CEO | S - Sale | $0.95 | -525,991 | 5,049,241 | -9% | -$499,691 | ||||||
2026-10-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $73.59 | -500 | 73,424 | -1% | -$36,795 | ||||||
2026-10-13 | ZONE | Zone Frontier Inc. | Hassen Tyler Lewis | CEO | P - Purchase | $0.12 | +1,250,000 | 3,250,000 | +63% | +$146,075 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $28.48 | -13,692 | 617,341 | -2% | -$389,948 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $28.48 | -9,218 | 141,467 | -6% | -$262,529 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $28.48 | -8,863 | 181,487 | -5% | -$252,418 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $28.48 | -5,245 | 115,241 | -4% | -$149,378 | |||||
2026-10-12 | LQDA | Liquidia Corp | Khindri Sanjeev | Chief Development Officer | S - Sale | $28.48 | -1,101 | 64,846 | -2% | -$31,356 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $28.48 | -18,938 | 340,148 | -5% | -$539,354 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $28.48 | -32,744 | 2,214,110 | -1% | -$932,549 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $28.48 | -5,892 | 165,609 | -3% | -$167,804 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $28.48 | -7,301 | 177,957 | -4% | -$207,932 | |||||
| DM | 2026-10-09 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $25.81 | -35,643 | 377,802 | -9% | -$919,870 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Keller Eric L. | CEO | P - Purchase | $12.00 | +20,800 | 464,407 | +5% | +$249,600 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Berger Franklin M | Dir | P - Purchase | $12.00 | +10,000 | 22,517 | +80% | +$120,000 | |||||
| M | 2026-10-08 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.03 | +14,632 | 2,873,289 | +1% | +$29,683 | |||||
| D | 2026-10-09 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.26 | -192 | 105,272 | 0% | -$12,338 | |||||
2026-10-12 | LYEL | Lyell Immunopharma, Inc. | Aguirre Jarrad Mattieu | Chief Medical Officer | S - Sale | $8.63 | -422 | 19,857 | -2% | -$3,642 | ||||||
2026-10-08 | OCUL | Ocular Therapeutix, Inc | Anderman Todd | GC | S - Sale | $7.29 | -11,984 | 140,484 | -8% | -$87,363 | ||||||
| D | 2026-10-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $80.60 | -9,999 | 14,219 | -41% | -$805,889 | |||||
| D | 2026-10-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $550.70 | -9,500 | 668,728 | -1% | -$5,231,666 | |||||
| D | 2026-10-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $544.94 | -9,500 | 668,728 | -1% | -$5,176,936 | |||||
| D | 2026-10-08 | TRXB | Trex Bio, Inc. | Svlsf Vi, LLC | 10% | P - Purchase | $14.00 | +92,857 | 3,011,818 | +3% | +$1,299,998 | |||||
| D | 2026-10-12 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $11.25 | -20,000 | 417,225 | -5% | -$224,948 | |||||
2026-10-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $156.31 | -2,462 | 98,114 | -2% | -$384,823 | ||||||
| D | 2026-10-12 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $62.88 | -7,500 | 282,710 | -3% | -$471,600 | |||||
2026-10-09 | NEOG | Neogen Corp | Nassif Mikheal | CEO | P - Purchase | $11.95 | +505 | 1,579 | +47% | +$6,035 | ||||||
| D | 2026-10-08 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale+OE | $36.32 | -6,000 | 62,284 | -9% | -$217,920 | |||||
| D | 2026-10-09 | ZYME | Zymeworks Inc. | Schayowitz Adam | EVP, Head of R, D | S - Sale+OE | $25.85 | -13,832 | 23,205 | -37% | -$357,557 | |||||
2026-10-07 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $63.39 | -2,500 | 1,457,360 | 0% | -$158,480 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $32.06 | -3,809 | 201,532 | -2% | -$122,117 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $32.06 | -1,327 | 175,218 | -1% | -$42,544 | ||||||
2026-10-07 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $32.06 | -2,241 | 217,060 | -1% | -$71,846 | ||||||
| M | 2026-10-08 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $94.07 | -63,209 | 39,218,111 | 0% | -$5,945,855 | |||||
| D | 2026-10-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $534.31 | -9,500 | 668,728 | -1% | -$5,075,919 | |||||
| D | 2026-10-08 | URGN | Urogen Pharma Ltd. | Degnan Chris | CFO | S - Sale+OE | $36.69 | -2,202 | 4,561 | -33% | -$80,791 | |||||
| M | 2026-10-07 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.47 | +215,000 | 1,643,000 | +15% | +$1,821,054 | |||||
2026-10-08 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.90 | +5,000 | 15,000 | +50% | +$44,500 | ||||||
| DM | 2026-10-06 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $110.18 | -60,000 | 767,780 | -7% | -$6,610,501 | |||||
| D | 2026-10-06 | IDYA | Ideaya Biosciences, Inc. | Hata Yujiro S | Pres, CEO | S - Sale+OE | $37.41 | -26,338 | 690,695 | -4% | -$985,397 | |||||
| DM | 2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $26.60 | -35,643 | 377,802 | -9% | -$948,223 | |||||
2026-10-06 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $30.00 | -6,444 | 389,350 | -2% | -$193,320 | ||||||
| M | 2026-10-06 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +10,903 | 945,924 | +1% | +$14,484 | |||||
| D | 2026-10-06 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $60.04 | -1,990 | 94,784 | -2% | -$119,481 | |||||
2026-10-07 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $18.10 | -48,199 | 1,358,204 | -3% | -$872,402 | ||||||
2026-10-06 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.59 | -17,717 | 105,134 | -14% | -$329,322 | ||||||
| D | 2026-10-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.95 | -9,500 | 668,728 | -1% | -$5,215,015 | |||||
| M | 2026-10-06 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $31.68 | -4,522 | 554,703 | -1% | -$143,273 | |||||
| D | 2026-10-07 | FUL | Fuller H B Co | Bailly R Jeffrey | Dir | P - Purchase | $50.00 | +10,000 | 10,000 | New | +$500,000 | |||||
| A | 2026-10-05 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $3.76 | -356 | 89,602 | 0% | -$1,339 | |||||
2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.84 | -50,000 | 6,108,287 | -1% | -$242,000 | ||||||
| D | 2026-10-06 | RXRX | Recursion Pharmaceuticals, Inc. | Hershberg Robert | Dir | S - Sale+OE | $5.00 | -25,000 | 162,156 | -13% | -$125,000 | |||||
2026-10-06 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $236.40 | -2,000 | 141,394 | -1% | -$472,800 | ||||||
| DM | 2026-10-05 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.06 | -2,073 | 105,272 | -2% | -$132,791 | |||||
2026-10-07 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $95.86 | -24,000 | 39,281,320 | 0% | -$2,300,633 | ||||||
2026-10-05 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $12.92 | -58,333 | 709,153 | -8% | -$753,937 | ||||||
2026-10-05 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $1.99 | -294 | 81,715 | 0% | -$585 | ||||||
2026-10-05 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale | $15.00 | -2,403 | 49,448 | -5% | -$36,045 | ||||||
| D | 2026-10-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.68 | -9,500 | 668,728 | -1% | -$5,117,412 | |||||
2026-10-05 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $27.13 | -235,477 | 104,570 | -69% | -$6,387,596 | ||||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale+OE | $86.74 | -18,000 | 145,435 | -11% | -$1,561,320 | |||||
| D | 2026-10-05 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $86.74 | -19,000 | 27,860 | -41% | -$1,648,060 | |||||
| D | 2026-10-05 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $202.15 | -4,548 | 562,760 | -1% | -$919,374 | |||||
2026-10-06 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $7.20 | -23,463 | 1,519,606 | -2% | -$168,880 | ||||||
2026-10-05 | AMLX | Amylyx Pharmaceuticals, Inc. | Milne George M Jr | Dir | S - Sale | $27.70 | -30,000 | 782,881 | -4% | -$830,904 | ||||||
2026-10-07 | EBS | Emergent Biosolutions Inc. | Degolyer Donald W | Dir | S - Sale | $7.09 | -17,800 | 111,921 | -14% | -$126,202 | ||||||
| M | 2026-10-05 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $8.64 | +10,000 | 10,000 | New | +$86,350 | |||||
2026-10-06 | AGMB | Agomab Therapeutics Nv | Kemula Pierre Thadee Victor | CFO | P - Purchase | $8.59 | +10,000 | 10,000 | New | +$85,940 | ||||||
| M | 2026-10-05 | AGMB | Agomab Therapeutics Nv | Knotnerus Tim Jasper | CEO | P - Purchase | $8.58 | +11,000 | 56,217 | +24% | +$94,380 | |||||
2026-10-06 | MGTX | Meiragtx Holdings Plc | Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY | S - Sale | $10.64 | -27,659 | 613,187 | -4% | -$294,292 | ||||||
2026-10-05 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $10.75 | -25,000 | 2,777,788 | -1% | -$268,760 | ||||||
| D | 2026-10-02 | IBRX | Immunitybio, Inc. | Cohen Cheryl | Dir | S - Sale+OE | $10.50 | -81,056 | 100,309 | -45% | -$851,088 | |||||
2026-10-02 | PTHS | Pelthos Therapeutics Inc. | Greenleaf Peter | Dir | S - Sale | $21.17 | -797 | 23,087 | -3% | -$16,872 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |